NCT02014883View on ClinicalTrials.gov

Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 4, 2013

Primary Completion Date

July 4, 2019

Study Completion Date

July 4, 2019

Conditions

Glut1 Deficiency Syndrome

Interventions

DRUG

GLUT1 DS

Trial Locations (1)

75013

Brain and Spine Institute, Paris

All Listed Sponsors

collaborator

Ultragenyx Pharmaceutical Inc

INDUSTRY

lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

NCT02014883 - Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS | Biotech Hunter | Biotech Hunter